

Kaleb Michaud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4957346/publications.pdf>

Version: 2024-02-01

191
papers

13,883
citations

27035

58
h-index

25230

113
g-index

196
all docs

196
docs citations

196
times ranked

12574
citing authors

#	ARTICLE	IF	CITATIONS
1	Influence of Multimorbidity on New Treatment Initiation and Achieving Target Disease Activity Thresholds in Active Rheumatoid Arthritis: A Cohort Study Using the Rheumatology Informatics System for Effectiveness Registry. <i>Arthritis Care and Research</i> , 2023, 75, 231-239.	1.5	6
2	Reduction of Cardiovascular Disease and Mortality Versus Risk of New Onset Diabetes Mellitus With Statin Use in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2023, 75, 597-607.	1.5	7
3	Knee joint unloading and daily physical activity associate with cartilage T2 relaxation times 1 month after ACL injury. <i>Journal of Orthopaedic Research</i> , 2022, 40, 138-149.	1.2	13
4	Increase in Cannabis Use Among Adults With Rheumatic Diseases: Results From a 2014–2019 United States Observational Study. <i>Arthritis Care and Research</i> , 2022, 74, 2091-2099.	1.5	10
5	Diabetes-Related Complications and Costs in Medicare Beneficiaries with Comorbid Rheumatoid Arthritis and Diabetes Treated with Abatacept Versus Other Targeted DMARDs. <i>Rheumatology and Therapy</i> , 2022, 9, 1091-1107.	1.1	1
6	2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. <i>Arthritis Care and Research</i> , 2022, 74, 1399-1408.	1.5	21
7	2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. <i>Arthritis and Rheumatology</i> , 2022, 74, 1464-1473.	2.9	12
8	Adaptation of American College of Rheumatology Rheumatoid Arthritis Disease Activity and Functional Status Measures for Telehealth Visits. <i>Arthritis Care and Research</i> , 2021, 73, 1809-1814.	1.5	22
9	Incidence, Prevalence, and Burden of Gout in the Veterans Health Administration. <i>Arthritis Care and Research</i> , 2021, 73, 1363-1371.	1.5	15
10	Obesity and the Risk of Incident Chronic Opioid Use in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1405-1412.	1.5	9
11	Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 1606-1616.	1.5	35
12	Defining Pain That Does Not Interfere With Activities Among Rheumatoid Arthritis Patients. <i>Arthritis Care and Research</i> , 2021, 73, 626-632.	1.5	4
13	Acceptability and Content Validity of Patient-Reported Outcome Measures Considered From the Perspective of Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 510-519.	1.5	6
14	Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 286-292.	0.5	35
15	Self-Management of Rheumatoid Arthritis: Mobile Applications. <i>Current Rheumatology Reports</i> , 2021, 23, 2.	2.1	15
16	The Risk of Cardiovascular Events Associated With Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 648-655.	1.0	56
17	Driving Ability and Safety in Rheumatoid Arthritis: A Systematic Review. <i>Arthritis Care and Research</i> , 2021, 73, 489-497.	1.5	8
18	The Impact of Asthma and Chronic Obstructive Pulmonary Disease (COPD) on Patient-Reported Outcomes in Systemic Lupus Erythematosus (SLE). <i>ACR Open Rheumatology</i> , 2021, 3, 221-230.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Risk of COVID-19 in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study in At-Risk Individuals. <i>Arthritis and Rheumatology</i> , 2021, 73, 2179-2188.	2.9	89
20	Outcomes of a Mobile App to Monitor Patient-Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 1421-1429.	2.9	19
21	Risk factors for venous thromboembolism and atherosclerotic cardiovascular disease: do they differ in patients with rheumatoid arthritis?. <i>RMD Open</i> , 2021, 7, e001618.	1.8	12
22	Effects of the SARS-CoV-2 global pandemic on U.S. rheumatology outpatient care delivery and use of telemedicine: an analysis of data from the RISE registry. <i>Rheumatology International</i> , 2021, 41, 1755-1761.	1.5	12
23	Vehicle Control as a Measure of Real-World Driving Performance in Patients with Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, , .	1.5	2
24	Changes in Disease-Modifying Antirheumatic Drug Treatment for Patients With Rheumatoid Arthritis in the US During the COVID-19 Pandemic: A Three-Month Observational Study. <i>Arthritis Care and Research</i> , 2021, 73, 1322-1331.	1.5	12
25	The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy. <i>Annals of Internal Medicine</i> , 2021, 174, 1510-1518.	2.0	18
26	OPEX: Development of a novel overall patient experience measure to facilitate interpretation of comparison effectiveness studies. <i>PLoS ONE</i> , 2021, 16, e0245598.	1.1	6
27	Response to: "Association of proton pump inhibitors with fracture risk in patients with rheumatoid arthritis" by Sugiyama. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e111-e111.	0.5	0
28	Systematic Review and Appraisal of the Cross-Cultural Validity of Functional Status Assessment Measures in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 798-805.	1.5	6
29	Changes in Alcohol Use and Associations With Disease Activity, Health Status, and Mortality in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 301-308.	1.5	13
30	Development of Resilience Among Rheumatoid Arthritis Patients: A Qualitative Study. <i>Arthritis Care and Research</i> , 2020, 72, 1257-1265.	1.5	19
31	Measures of Rheumatoid Arthritis Disease Activity. <i>Arthritis Care and Research</i> , 2020, 72, 4-26.	1.5	9
32	Reply. <i>Arthritis Care and Research</i> , 2020, 72, 1340-1340.	1.5	0
33	Reply. <i>Arthritis Care and Research</i> , 2020, 72, 1509-1510.	1.5	0
34	Posttraumatic Stress Disorder, Depression, Anxiety, and Persistence of Methotrexate and TNF Inhibitors in Patients with Rheumatoid Arthritis. <i>ACR Open Rheumatology</i> , 2020, 2, 555-564.	0.9	4
35	Probiotic Use and Psoriatic Arthritis Disease Activity. <i>ACR Open Rheumatology</i> , 2020, 2, 330-334.	0.9	7
36	Defining Minimally Important Changes for the Patient Activity Scale. <i>Arthritis Care and Research</i> , 2020, 73, 1456-1460.	1.5	1

#	ARTICLE	IF	CITATIONS
37	Response to: "Association between proton pump inhibitors therapy and fracture risk in patients with rheumatoid arthritis"™ by Lai <i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e157-e157.	0.5	0
38	Estimation of Minimally Important Differences and Patient Acceptable Symptom State Scores for the Patient-Reported Outcomes Measurement Information System Pain Interference Short Form in Rheumatoid Arthritis. ACR Open Rheumatology, 2020, 2, 320-329.	0.9	14
39	Patterns of Tumor Necrosis Factor Inhibitor (TNF i) Biosimilar Use Across United States Rheumatology Practices. ACR Open Rheumatology, 2020, 2, 79-83.	0.9	8
40	Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus. ACR Open Rheumatology, 2020, 2, 53-60.	0.9	32
41	Reply. Arthritis Care and Research, 2020, 72, 736-738.	1.5	0
42	All-cause and cause-specific mortality in persons with fibromyalgia and widespread pain: An observational study in 35,248 persons with rheumatoid arthritis, non-inflammatory rheumatic disorders and clinical fibromyalgia. Seminars in Arthritis and Rheumatism, 2020, 50, 1457-1464.	1.6	9
43	Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic. ACR Open Rheumatology, 2020, 2, 335-343.	0.9	131
44	Patient's experience of psoriatic arthritis: a conceptual model based on qualitative interviews. RMD Open, 2020, 6, e001321.	1.8	21
45	Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease-Modifying Antirheumatic Drugs. ACR Open Rheumatology, 2019, 1, 424-432.	0.9	39
46	Real-World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis. ACR Open Rheumatology, 2019, 1, 560-570.	0.9	11
47	Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 1268-1280.	0.5	1
48	2019 American College of Rheumatology Recommended Patient-Reported Functional Status Assessment Measures in Rheumatoid Arthritis. Arthritis Care and Research, 2019, 71, 1531-1539.	1.5	39
49	2019 Update of the American College of Rheumatology Recommended Rheumatoid Arthritis Disease Activity Measures. Arthritis Care and Research, 2019, 71, 1540-1555.	1.5	157
50	The Interface Between Digital Health and Rheumatology. Rheumatic Disease Clinics of North America, 2019, 45, xv-xvi.	0.8	0
51	Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open, 2019, 5, e000935.	1.8	92
52	Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial. Rheumatology and Therapy, 2019, 6, 409-419.	1.1	18
53	Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study. Arthritis Research and Therapy, 2019, 21, 141.	1.6	43
54	Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: A systematic literature review and meta-analysis. Seminars in Arthritis and Rheumatism, 2019, 49, 358-365.	1.6	56

#	ARTICLE	IF	CITATIONS
55	Medications associated with fracture risk in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1041-1047.	0.5	75
56	Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs. <i>Advances in Therapy</i> , 2019, 36, 1337-1357.	1.3	11
57	Mobile Apps for Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2019, 45, 197-209.	0.8	27
58	<p>Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient</p>. <i>ClinicoEconomics and Outcomes Research</i> , 2019, Volume 11, 117-128.	0.7	7
59	Is It Time to Banish Composite Measures for Remission in Rheumatoid Arthritis?. <i>Arthritis Care and Research</i> , 2019, 71, 1300-1303.	1.5	5
60	SAT0377â€¦DIFFERENCES IN CLINICAL CHARACTERISTICS, QUALITY OF LIFE, DISABILITY, AND WORK PRODUCTIVITY IN PSORIATIC ARTHRITIS PATIENTS BY GENDER: FINDINGS FROM A CROSS-SECTIONAL SURVEY IN THE US AND EUROPE. , 2019, , .		0
61	FRI0463â€¦ENTHESITIS, DACTYLITIS, AND AXIAL DISEASE IN PSORIATIC ARTHRITIS (PSA): IMPACT ON PATIENT QUALITY OF LIFE AND WORK PRODUCTIVITY. , 2019, , .		2
62	Response to: â€œMedications associated with fracture risk in patients with rheumatoid arthritisâ€™ by Chen et al. <i>Annals of the Rheumatic Diseases</i> , 2019, 80, annrhumdis-2019-216293.	0.5	2
63	OP0226â€¦SOLID TUMOUR OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY. , 2019, , .		2
64	FRI0118â€¦INFECTION OUTCOMES IN PATIENTS WITH RA TREATED WITH ABATACEPT AND OTHER DMARDS: RESULTS FROM A 10-YEAR INTERNATIONAL POST-APPROVAL STUDY. , 2019, , .		2
65	International Consortium for Health Outcome Measurement Set of Outcomes That Matter to People Living With Inflammatory Arthritis: Consensus From an International Working Group. <i>Arthritis Care and Research</i> , 2019, 71, 1556-1565.	1.5	43
66	Correlation of the Multiâ€œBiomarker Disease Activity Score With Rheumatoid Arthritis Disease Activity Measures: A Systematic Review and Metaâ€œAnalysis. <i>Arthritis Care and Research</i> , 2019, 71, 1459-1472.	1.5	28
67	Allopurinol Dose Escalation and Mortality Among Patients With Gout. <i>Arthritis and Rheumatology</i> , 2018, 70, 1298-1307.	2.9	26
68	Deriving common comorbidity indices from the MedDRA classification and exploring their performance on key outcomes in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 548-554.	0.9	15
69	Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. <i>Journal of Clinical Rheumatology</i> , 2018, 24, 203-209.	0.5	19
70	Malondialdehydeâ€œacetaldehyde antibody concentrations in rheumatoid arthritis and other rheumatic conditions. <i>International Immunopharmacology</i> , 2018, 56, 113-118.	1.7	20
71	Using technology to support clinical care and research in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 276-281.	2.0	41
72	The impact of menopause on functional status in women with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 798-802.	0.9	24

#	ARTICLE	IF	CITATIONS
73	Obesity, Weight Loss, and Progression of Disability in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 1740-1747.	1.5	22
74	Body Mass Index, Weight Loss, and Cause-specific Mortality in Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2018, 70, 11-18.	1.5	35
75	Rheumatoid Arthritis Patients' Motivations for Accepting or Resisting Disease-Modifying Antirheumatic Drug Treatment Regimens. <i>Arthritis Care and Research</i> , 2018, 70, 533-541.	1.5	18
76	Timing and Impact of Decisions to Adjust Disease-Modifying Antirheumatic Drug Therapy for Rheumatoid Arthritis Patients With Active Disease. <i>Arthritis Care and Research</i> , 2018, 70, 834-841.	1.5	5
77	Trends and Determinants of Osteoporosis Treatment and Screening in Patients With Rheumatoid Arthritis Compared to Osteoarthritis. <i>Arthritis Care and Research</i> , 2018, 70, 713-723.	1.5	15
78	Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survival. <i>Clinical Rheumatology</i> , 2018, 37, 2907-2915.	1.0	19
79	Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0205013.	1.1	9
80	The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 4-11.	0.5	23
81	A Mobile App With Optical Imaging for the Self-Management of Hand Rheumatoid Arthritis: Pilot Study. <i>JMIR MHealth and UHealth</i> , 2018, 6, e12221.	1.8	45
82	A Novel Mobile App and Population Management System to Manage Rheumatoid Arthritis Flares: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2018, 7, e84.	0.5	13
83	Validity and Responsiveness of a 10-item Patient-Reported Measure of Physical Function in a Rheumatoid Arthritis Clinic Population. <i>Arthritis Care and Research</i> , 2017, 69, 338-346.	1.5	32
84	Response to: "Statin therapy now more common than steroids in clinical practice" by Pareek and Chankurdar. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e19-e19.	0.5	1
85	Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 848-854.	0.5	64
86	Impact of Obesity and Adiposity on Inflammatory Markers in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 1789-1798.	1.5	56
87	Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. <i>Rheumatology International</i> , 2017, 37, 1551-1557.	1.5	313
88	Performance of the Patient-Reported Outcomes Measurement Information System 29-item Profile in Rheumatoid Arthritis, Osteoarthritis, Fibromyalgia, and Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017, 69, 1312-1321.	1.5	71
89	Modelling the cost-effectiveness of statin therapy in rheumatoid arthritis: a Markov-cycle evaluation from national data bank for rheumatic diseases. <i>Journal of Pharmaceutical Health Services Research</i> , 2017, 8, 139-145.	0.3	0
90	Infection rates in patients from five rheumatoid arthritis (RA) registries: contextualising an RA clinical trial programme. <i>RMD Open</i> , 2017, 3, e000498.	1.8	25

#	ARTICLE	IF	CITATIONS
91	Utilization of Care Outside the Veterans Affairs Health Care System by US Veterans With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 776-782.	1.5	17
92	O09.â€fECONOMIC BURDEN OF RHEUMATOID ARTHRITIS IS HIGHER FOR ANTI-CITRULLINATED PROTEIN ANTIBODY: POSITIVE PATIENTS. <i>Rheumatology</i> , 2017, 56, .	0.9	0
93	Risk of Incident Diabetes Mellitus Associated With the Dosage and Duration of Oral Glucocorticoid Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1089-1098.	2.9	83
94	Associations of Circulating Cytokines and Chemokines With Cancer Mortality in Men With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2394-2402.	2.9	17
95	Changes in Body Mass Related to the Initiation of Diseaseâ€Modifying Therapies in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1818-1827.	2.9	34
96	Clinical Outcomes and Biologic Costs of Switching Between Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. <i>Advances in Therapy</i> , 2016, 33, 1347-1359.	1.3	16
97	How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1789-1796.	0.5	18
98	Patient-Reported Outcomes in Rheumatoid Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2016, 42, 219-237.	0.8	29
99	A PROMIS Measure of Neuropathic Pain Quality. <i>Value in Health</i> , 2016, 19, 623-630.	0.1	39
100	Causeâ€Specific Mortality in Male US Veterans With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 36-45.	1.5	103
101	Rheumatology Informatics System for Effectiveness: A National Informaticsâ€Enabled Registry for Quality Improvement. <i>Arthritis Care and Research</i> , 2016, 68, 1866-1873.	1.5	61
102	Crowdsourced assessment of common genetic contribution to predicting anti-TNF treatment response in rheumatoid arthritis. <i>Nature Communications</i> , 2016, 7, 12460.	5.8	73
103	Increasing Public Health Burden of Arthritis and Other Rheumatic Conditions and Comorbidity: Results From a Statewide Health Surveillance System, 2007â€2012. <i>Arthritis Care and Research</i> , 2016, 68, 1417-1427.	1.5	13
104	Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. <i>Arthritis Care and Research</i> , 2016, 68, 1478-1488.	1.5	54
105	Costâ€Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2016, 68, 1751-1757.	1.5	27
106	Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1797-1805.	0.5	16
107	The National Data Bank for Rheumatic Diseases (NDB). <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S100-S101.	0.4	13
108	Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?. <i>RMD Open</i> , 2015, 1, e000155-e000155.	1.8	34

#	ARTICLE	IF	CITATIONS
109	Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1121-1132.	0.9	6
110	Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries. <i>Arthritis Care and Research</i> , 2015, 67, 1637-1645.	1.5	16
111	Weight Loss, the Obesity Paradox, and the Risk of Death in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1711-1717.	2.9	84
112	Impact of Total Knee Arthroplasty as Assessed Using Patient-Reported Pain and Health-Related Quality of Life Indices: Rheumatoid Arthritis Versus Osteoarthritis. <i>Arthritis and Rheumatology</i> , 2015, 67, 2503-2511.	2.9	37
113	Associations of toll-like receptor (TLR)-4 single nucleotide polymorphisms and rheumatoid arthritis disease progression: An observational cohort study. <i>International Immunopharmacology</i> , 2015, 24, 346-352.	1.7	28
114	Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 1640-1649.	0.9	13
115	Validation of the Rheumatic Disease Comorbidity Index. <i>Arthritis Care and Research</i> , 2015, 67, 865-872.	1.5	177
116	Associations of Hydroxychloroquine Use With Lipid Profiles in Rheumatoid Arthritis: Pharmacologic Implications. <i>Arthritis Care and Research</i> , 2014, 66, 1619-1626.	1.5	60
117	Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 1935-1943.	1.0	25
118	Strong Association of Health Literacy With Functional Status Among Rheumatoid Arthritis Patients: A Cross-sectional Study. <i>Arthritis Care and Research</i> , 2014, 66, 508-514.	1.5	39
119	Rheumatoid Factor as a Potentiator of Anti-Citrullinated Protein Antibody-Mediated Inflammation in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, 813-821.	2.9	174
120	Polysymptomatic Distress in Patients With Rheumatoid Arthritis: Understanding Disproportionate Response and Its Spectrum. <i>Arthritis Care and Research</i> , 2014, 66, 1465-1471.	1.5	43
121	Rheumatoid arthritis patients are not at increased risk for 30-day cardiovascular events, infections, or mortality after total joint arthroplasty. <i>Arthritis Research and Therapy</i> , 2013, 15, R195.	1.6	27
122	Prospective study of posttraumatic stress disorder and disease activity outcomes in US veterans with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 227-234.	1.5	46
123	Associations of Alcohol Use with Radiographic Disease Progression in African Americans with Recent-onset Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1498-1504.	1.0	7
124	Bisphosphonate use is associated with reduced risk of myocardial infarction in patients with rheumatoid arthritis. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 984-991.	3.1	60
125	Reply. <i>Arthritis Care and Research</i> , 2013, 65, 835-835.	1.5	2
126	Mortality Risk by Functional Status and Health-related Quality of Life in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2012, 39, 54-59.	1.0	51

#	ARTICLE	IF	CITATIONS
127	Validity and Reliability Problems with Patient Global as a Component of the ACR/EULAR Remission Criteria as Used in Clinical Practice. <i>Journal of Rheumatology</i> , 2012, 39, 1139-1145.	1.0	57
128	Impact of Total Shoulder Arthroplasty on Generic and Shoulder-Specific Health-Related Quality-of-Life Measures. <i>Journal of Bone and Joint Surgery - Series A</i> , 2012, 94, e127.	1.4	105
129	Effect of body mass index on mortality and clinical status in rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1471-1479.	1.5	108
130	Effects of infertility, pregnancy loss, and patient concerns on family size of women with rheumatoid arthritis and systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2012, 64, 668-674.	1.5	132
131	Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. <i>Arthritis Care and Research</i> , 2012, 64, 640-647.	1.5	566
132	Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: A longitudinal study of 18,485 patients. <i>Arthritis Care and Research</i> , 2011, 63, 366-372.	1.5	37
133	Minocycline and doxycycline therapy in community patients with rheumatoid arthritis: prescribing patterns, patient-level determinants of use, and patient-reported side effects. <i>Arthritis Research and Therapy</i> , 2011, 13, R168.	1.6	34
134	Mortality in fibromyalgia: A study of 8,186 patients over thirty-five years. <i>Arthritis Care and Research</i> , 2011, 63, 94-101.	1.5	93
135	Measures of functional status and quality of life in rheumatoid arthritis: Health Assessment Questionnaire Disability Index (HAQ), Modified Health Assessment Questionnaire (MHAQ), Multidimensional Health Assessment Questionnaire (MDHAQ), Health Assessment Questionnaire II (HAQ-II), Improved Health Assessment Questionnaire (Improved HAQ), and Rheumatoid Arthritis Quality	1.5	223
136	Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5. <i>Arthritis Care and Research</i> , 2011, 63, S14-36.	1.5	202
137	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
138	Remission of rheumatoid arthritis in clinical practice: Application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. <i>Arthritis and Rheumatism</i> , 2011, 63, 3204-3215.	6.7	75
139	The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. <i>Rheumatology</i> , 2011, 50, 16-24.	0.9	113
140	Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. <i>Rheumatology</i> , 2011, 50, 101-109.	0.9	80
141	A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 2-14.e1.	1.6	161
142	Development and initial validation of a self-assessed lupus organ damage instrument. <i>Arthritis Care and Research</i> , 2010, 62, 559-568.	1.5	40
143	Converting modified health assessment questionnaire (HAQ), multidimensional HAQ, and HAQII scores into original HAQ scores using models developed with a large cohort of rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2010, 62, 1481-1488.	1.5	34
144	The Hawthorne Effect, Sponsored Trials, and the Overestimation of Treatment Effectiveness. <i>Journal of Rheumatology</i> , 2010, 37, 2216-2220.	1.0	47

#	ARTICLE	IF	CITATIONS
145	Scale Characteristics and Mapping Accuracy of the US EQ-5D, UK EQ-5D, and SF-6D in Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1615-1625.	1.0	17
146	Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1292-1297.	0.5	86
147	EQ-5D and SF-36 Quality of Life Measures in Systemic Lupus Erythematosus: Comparisons with Rheumatoid Arthritis, Noninflammatory Rheumatic Disorders, and Fibromyalgia. <i>Journal of Rheumatology</i> , 2010, 37, 296-304.	1.0	91
148	Chronic Conditions and Health Problems in Rheumatic Diseases: Comparisons with Rheumatoid Arthritis, Noninflammatory Rheumatic Disorders, Systemic Lupus Erythematosus, and Fibromyalgia. <i>Journal of Rheumatology</i> , 2010, 37, 305-315.	1.0	123
149	The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study. <i>Arthritis Research and Therapy</i> , 2010, 12, R35.	1.6	52
150	Proposed Metrics for the Determination of Rheumatoid Arthritis Outcome and Treatment Success and Failure. <i>Journal of Rheumatology</i> , 2009, 36, 27-33.	1.0	21
151	Outcome and Predictor Relationships in Fibromyalgia and Rheumatoid Arthritis: Evidence Concerning the Continuum versus Discrete Disorder Hypothesis. <i>Journal of Rheumatology</i> , 2009, 36, 831-836.	1.0	31
152	Predicting depression in rheumatoid arthritis: The signal importance of pain extent and fatigue, and comorbidity. <i>Arthritis and Rheumatism</i> , 2009, 61, 667-673.	6.7	160
153	Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1563-1570.	6.7	34
154	Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2009, 11, 229.	1.6	682
155	Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis. <i>Arthritis and Rheumatism</i> , 2008, 58, 939-946.	6.7	82
156	The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: A cohort and nested case-control analysis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2612-2621.	6.7	142
157	Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: A nested, case-control study. <i>Arthritis and Rheumatism</i> , 2008, 59, 1090-1096.	6.7	104
158	The challenges of determining RA disease activity and remission in clinical practice. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 462-463.	3.2	5
159	The problem of rheumatoid arthritis disease activity and remission in clinical practice. <i>Journal of Rheumatology</i> , 2008, 35, 1015-22.	1.0	40
160	Prevalence, risk, and risk factors for oral and ocular dryness with particular emphasis on rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2008, 35, 1023-30.	1.0	20
161	The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON-YEARS of observation. <i>Arthritis and Rheumatism</i> , 2007, 56, 1433-1439.	6.7	327
162	Resistance of rheumatoid arthritis patients to changing therapy: Discordance between disease activity and patients' treatment choices. <i>Arthritis and Rheumatism</i> , 2007, 56, 2135-2142.	6.7	113

#	ARTICLE	IF	CITATIONS
163	Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. <i>Arthritis and Rheumatism</i> , 2007, 56, 2886-2895.	6.7	498
164	Minimal disease activity, remission, and the long-term outcomes of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 935-942.	6.7	54
165	Comorbidities in rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 885-906.	1.4	333
166	Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. <i>Journal of Rheumatology</i> , 2007, 34, 696-705.	1.0	77
167	Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. <i>Journal of Rheumatology</i> , 2007, 34, 1674-83.	1.0	109
168	The prevalence and incidence of work disability in rheumatoid arthritis, and the effect of anti-tumor necrosis factor on work disability. <i>Journal of Rheumatology</i> , 2007, 34, 2211-7.	1.0	46
169	Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: Associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. <i>Arthritis and Rheumatism</i> , 2006, 54, 628-634.	6.7	422
170	Fibromyalgia diagnosis: A comparison of clinical, survey, and American College of Rheumatology criteria. <i>Arthritis and Rheumatism</i> , 2006, 54, 169-176.	6.7	181
171	Anemia and renal function in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2006, 33, 1516-22.	1.0	44
172	Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. <i>Journal of Rheumatology</i> , 2006, 33, 1942-51.	1.0	111
173	Work disability and its economic effect on 55-64-year-old adults with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 53, 603-608.	6.7	62
174	The Disease Activity Score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic: Discordance between assessment measures and limitations in questionnaire use for regulatory purposes. <i>Arthritis and Rheumatism</i> , 2005, 52, 3873-3879.	6.7	58
175	Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 583-9.	1.0	50
176	Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients. <i>Journal of Rheumatology</i> , 2005, 32, 1006-12.	1.0	59
177	Preliminary evaluation of a visual analog function scale for use in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1261-6.	1.0	24
178	Household income and earnings losses among 6,396 persons with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 1875-83.	1.0	61
179	Minimal disease activity for rheumatoid arthritis: a preliminary definition. <i>Journal of Rheumatology</i> , 2005, 32, 2016-24.	1.0	132
180	Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. <i>Journal of Rheumatology</i> , 2005, 32, 2130-5.	1.0	155

#	ARTICLE	IF	CITATIONS
181	A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS/PAS-II). <i>Journal of Rheumatology</i> , 2005, 32, 2410-5.	1.0	88
182	Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. <i>Arthritis and Rheumatism</i> , 2004, 50, 372-379.	6.7	382
183	Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. <i>Arthritis and Rheumatism</i> , 2004, 50, 1740-1751.	6.7	787
184	Development and validation of the health assessment questionnaire II: A revised version of the health assessment questionnaire. <i>Arthritis and Rheumatism</i> , 2004, 50, 3296-3305.	6.7	231
185	Data collection, maintenance, and analysis for rheumatic disease research. <i>Rheumatic Disease Clinics of North America</i> , 2004, 30, 753-768.	0.8	5
186	Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. <i>American Journal of Medicine</i> , 2004, 116, 305-311.	0.6	331
187	Rheumatoid arthritis and heart failure: The reply. <i>American Journal of Medicine</i> , 2004, 117, 709.	0.6	0
188	Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. <i>Journal of Rheumatology</i> , 2004, 31, 355-8.	1.0	15
189	Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize ra patients with fibromyalgia. <i>Journal of Rheumatology</i> , 2004, 31, 695-700.	1.0	169
190	Predicting mortality in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 1530-1542.	6.7	224
191	Direct medical costs and their predictors in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2003, 48, 2750-2762.	6.7	238